TWA
SPRO icon

TCI Wealth Advisors’s Spero Therapeutics SPRO Stock Holding History

TCI Wealth Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-146
Closed -$3K – 2505
2021
Q3 		$3K Hold
146
– – ﹤0.01% 2011
2021
Q2 		$2K Hold
146
– – ﹤0.01% 2089
2021
Q1 		$2K Buy
+146
New +$2.57K ﹤0.01% 1892

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

TCI Wealth Advisors's SPRO Position: Q4 2021 in Review

TCI Wealth Advisors sold out of Spero Therapeutics (SPRO) in Q4 2021, closing a stake of 146 shares — an estimated $3K sold.

TCI Wealth Advisors first reported a position in SPRO in Q1 2021 and held it in 3 quarters. The position peaked at $3K in Q3 2021. 84 funds tracked by Wall St. Rank hold SPRO as of Q4 2021.

  • TCI Wealth Advisors reported no remaining Spero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • TCI Wealth Advisors sold 146 Spero Therapeutics shares in Q4 2021, an estimated $3K.
  • TCI Wealth Advisors first reported a position in Spero Therapeutics in Q1 2021 and held it in 3 quarters.
  • TCI Wealth Advisors's Spero Therapeutics position peaked at $3K in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2021.

Based on TCI Wealth Advisors's 13F filing for Q4 2021, filed 24 Jan 2022.